Leah M. Chase

Leah M. Chase

Auto-generated profile, based on publicly available information

Leah M. Chase

Irvine School of Medicine University of California 1001 Health Sciences Rd 92617 Irvine CA USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SMSteven B. Maron
Steven B. Maron
LALindsay Alpert
Lindsay Alpert
HKHeewon A. Kwak
Heewon A. Kwak
SLSamantha Lomnicki
Samantha Lomnicki
LCLeah Chase
Leah Chase
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
Previous anti-EGFR trials in unselected patients with gastroesophageal adenocarcinoma (GEA) were resoundingly negative. We identified EGFR amplification in 5% (19/363) of patients at the University of Chicago, including 6% (8/140) who were prospectively screened with intention-to-treat using anti-EGFR therapy. Seven patients received ≥1 dose of treatment: three first-line FOLFOX plus ABT-806, one second-line FOLFIRI plus cetuximab, and three third/fourth-line cetuximab alone. Treatment achieved objective response in 58% (4/7) and disease control in 100% (7/7) with a median progression-free survival of 10 months. Pretreatment and posttreatment tumor next-generation sequencing (NGS), serial plasma circulating tumor DNA (ctDNA) NGS, and tumor IHC/FISH for EGFR revealed preexisting and/or acquired genomic events, including EGFR-negative clones, PTEN deletion, KRAS amplification/mutation, NRAS, MYC, and HER2 amplification, and GNAS mutations serving as mechanisms of resistance. Two evaluable patients demonstrated interval increase of CD3+ infiltrate, including one who demonstrated increased NKp46+, and PD-L1 IHC expression from baseline, suggesting an immune therapeutic mechanism of action. EGFR amplification predicted benefit from anti-EGFR therapy, albeit until various resistance mechanisms emerged. Significance: This paper highlights the role of EGFR inhibitors in EGFR-amplified GEA—despite negative results in prior unselected phase III trials. Using serial ctDNA and tissue NGS, we identified mechanisms of primary and acquired resistance in all patients, as well as potential contribution of antibody-dependent cell-mediated cytotoxicity to their clinical benefit. Cancer Discov; 8(6); 696–713. ©2018 AACR. See related commentary by Strickler, p. 679. This article is highlighted in the In This Issue feature, p. 663

23 June 2023 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
LCLeah M. Chase
Leah M. Chase
SSShaina Sedighim
Shaina Sedighim
CLCarlin Lee
Carlin Lee
MHMennatalla Hegazi
Mennatalla Hegazi
HKHari Balaji Keshava
Hari Balaji Keshava
AMAli Mahtabifard
Ali Mahtabifard

3 April 2023
Verified
Other
Open access
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
SMStephanie Moya
Stephanie Moya
SLSamantha Lomnicki
Samantha Lomnicki
LCLeah M. Chase
Leah M. Chase
BPBryan F. Peterson
Bryan F. Peterson
HKHedy L. Kindler
Hedy L. Kindler

3 April 2023
Verified
Other
Open access
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
SMStephanie Moya
Stephanie Moya
SLSamantha Lomnicki
Samantha Lomnicki
LCLeah M. Chase
Leah M. Chase
BPBryan F. Peterson
Bryan F. Peterson
HKHedy L. Kindler
Hedy L. Kindler

1 October 2016 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
JBJordan D. Bowling
Jordan D. Bowling
MIMubina Isani
Mubina Isani
JGJamie M. Golden
Jamie M. Golden
ADAvafia Dossa
Avafia Dossa
LCLeah M. Chase
Leah M. Chase
HFHenri R. Ford
Henri R. Ford

3 April 2023
Verified
Other
Open access
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
SMStephanie Moya
Stephanie Moya
SLSamantha Lomnicki
Samantha Lomnicki
LCLeah M. Chase
Leah M. Chase
BPBryan F. Peterson
Bryan F. Peterson
HKHedy L. Kindler
Hedy L. Kindler